Bio
Hedra Therapeutics is an early-stage biotechnology company developing novel, fast-acting treatments for severe neuropsychiatric conditions. Our work focuses on small-molecule candidates designed for rapid onset and clinical scalability. We are currently advancing our lead program through preclinical development and pursuing non-dilutive funding pathways to support translational progress. At Hedra, our mission is to create targeted interventions that respond to urgent, unmet needs in mental health care.